This is a faster-growing type of leukemia that happens after the chronic phase. It means the leukemia is getting worse more quickly. Symptoms like fatigue and infections might get worse, and your blood counts might drop further. It's a serious stage that needs prompt medical attention.
Every report comes from a Lived member, sent anonymously.
Have you tried Sprycel (Dasatinib) for Accelerated Myeloid Leukemia?
Accelerated myeloid leukemia is the accelerated phase of chronic myeloid leukemia (CML), a cancer of the bone marrow in which the marrow makes too many white blood cells. Doctors have traditionally described CML in three phases. Most people are diagnosed in chronic phase, when the disease is stable and responds well to treatment. Accelerated phase comes next, and blast phase (sometimes called blast crisis) is the most advanced, behaving much like an acute leukemia. In accelerated phase the leukemia has become harder to control. More immature cells called blasts appear in the blood and bone marrow, blood counts drift further out of range, and the leukemia cells may pick up new genetic changes. Some people notice few symptoms. Others have fever, poor appetite, weight loss, tiredness from anemia, or a growing sense of fullness under the left ribs from an enlarged spleen. This phase matters because it signals higher-risk disease that typically does not respond as well to treatment as chronic phase, and it can lead to blast phase. It can be found at diagnosis or develop in someone already being treated. Despite the similar name, it is not acute myeloid leukemia (AML), which is a separate disease treated differently. With modern treatment and regular monitoring, progression to this phase has become much less common than it once was.
CML starts with a genetic change acquired in a single blood-forming cell. Pieces of chromosome 9 and chromosome 22 swap places, creating what is called the Philadelphia chromosome and a fused gene called BCR-ABL1. That gene produces an overactive enzyme, a tyrosine kinase, that keeps pushing the marrow to make white blood cells. The change happens during a person's lifetime and is not passed from parent to child, and in most cases there is no known reason it occurred. Older age and exposure to high-dose radiation are the main known risk factors. Moving from chronic phase into accelerated phase happens as the leukemia cells gain further genetic changes. Often this goes hand in hand with treatment resistance: some cells develop mutations in the BCR-ABL1 gene that stop a particular medicine from working, or they acquire extra chromosome abnormalities. The best protection against progression is treatment that keeps the leukemia deeply suppressed, which is why response is checked regularly and treatment is changed when it falls short.
Accelerated phase is identified through blood and bone marrow tests, usually by a blood cancer specialist (a hematologist-oncologist). A complete blood count measures white cells, red cells and platelets, and examining the blood under a microscope shows what share of cells are blasts, immature cells that are normally rare. A bone marrow aspiration and biopsy, in which a small sample of marrow and bone is taken with a needle from the hipbone or breastbone after the skin is numbed, gives the blast and basophil percentages and shows how much scarring the marrow has. Under the definition used by the US National Cancer Institute, chronic phase has fewer than 10% blasts in the blood or marrow, accelerated phase has 10% to 19%, and blast phase has 20% or more. Other findings can also place someone in accelerated phase: basophils (another type of white blood cell) making up 20% or more of the blood, a platelet count of 100,000 or lower that is not caused by treatment, or new chromosome changes in the leukemia cells. Experts do not all use the same cutoffs, and the 2022 World Health Organization (WHO) classification no longer names an accelerated phase at all, focusing instead on treatment resistance and blast phase. Whatever the label, these findings mean higher-risk disease that needs closer attention. Genetic tests confirm the Philadelphia chromosome or the BCR-ABL1 gene. Chromosome analysis looks for additional changes, and when the leukemia is not responding to a medicine, a mutation test of the BCR-ABL1 gene shows which medicines are still likely to work.
Treatment aims to bring the leukemia back under control, ideally to the point where the BCR-ABL1 gene is barely detectable, and to decide early whether a stem cell transplant is needed. Accelerated phase is treated as high-risk disease and watched more closely than chronic phase. The main medicines are tyrosine kinase inhibitors (TKIs), daily pills that block the overactive BCR-ABL1 enzyme driving the leukemia. Imatinib (Gleevec) was the first. Dasatinib (Sprycel), nilotinib (Tasigna) and bosutinib (Bosulif) are newer, more potent TKIs approved for accelerated phase when an earlier treatment stopped working or could not be tolerated. Ponatinib (Iclusig) is used when no other TKI is suitable, or when the leukemia carries a resistance mutation called T315I. The choice depends on which medicines a person has already taken, the mutation test results and their other health conditions. Each TKI has its own side effect pattern, and that weighs heavily in the choice. Nilotinib and especially ponatinib raise the risk of narrowed or blocked arteries, so they are generally avoided in people with heart or blood vessel disease. Dasatinib can cause fluid to build up around the lungs and is generally avoided in people with existing lung disease. Bosutinib commonly causes diarrhea, which usually settles. Side effects lead to a change of medicine in up to about 30% of people, so switching is an ordinary part of finding the right fit. An allogeneic stem cell transplant replaces the person's blood-forming system with cells from a matched donor. It can cure some people with CML, but it carries a considerable risk of serious complications and death, including graft-versus-host disease, in which donor immune cells attack the body. Results are better when it is done earlier in the disease. Guidelines advise considering transplant for someone diagnosed in accelerated phase whose response to a TKI is not good enough, and promptly for someone whose CML moved into accelerated phase while on treatment. Because finding a donor takes time, a transplant team is often consulted early. Clinical trials of newer treatments may also be an option.
Accelerated phase is more serious than chronic phase, but it does not mean treatment options have run out. TKI treatment can bring the leukemia back into remission, although responses are usually less complete than in chronic phase, and some people need a different medicine or a transplant. The outlook depends on how quickly and deeply the leukemia responds, whether it carries resistance mutations or high-risk chromosome changes, and the person's age and overall health. Life on a TKI usually means taking a pill every day for the long term, with frequent blood tests. Early on, blood counts are checked about every 2 weeks, because low counts are common while the medicine clears leukemia cells and may need a temporary dose change. After that, a quantitative polymerase chain reaction (PCR) blood test, which measures how much BCR-ABL1 remains, is done at least every 3 months. Results are reported as a percentage on an international scale. Commonly used milestones are 10% or less at 3 months, 1% or less at 6 months, and 0.1% or less (a major molecular response) by 12 months. Reaching 0.1% or less means progression becomes uncommon. Missing a milestone, or a rising level, usually leads to mutation testing and a change in treatment. Side effects vary by medicine. Some, like diarrhea or constipation, can happen with any TKI, and many can be managed by adjusting the dose or switching medicines. Pregnancy needs planning: TKIs can harm a developing baby, so women who could become pregnant should discuss contraception and timing with their care team, and treatment is stopped in the first trimester as soon as a pregnancy is confirmed. For men taking imatinib, bosutinib, dasatinib or nilotinib, studies have not found a higher risk of birth defects in their children.
See a doctor about ongoing tiredness, unexplained weight loss or drenching night sweats, which can be signs of CML in someone not yet diagnosed. If you already have CML, keep every scheduled blood test, since that is how a shift toward accelerated phase is caught early. Contact your care team promptly if you develop a new fever, bone pain, unusual bruising or bleeding, or fullness or pain under the left ribs that is growing or becoming painful (a sign of an enlarging spleen). These can mean the leukemia is moving toward blast phase. Also call if side effects make it hard to keep taking your medicine, before changing or stopping a dose, and if you become pregnant while on treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Accelerated Myeloid Leukemia is like, what's helped you, or ask the community a question.